Breaking News Headlines Today

News from urologytime.com

All of today’s top news stories from urologytime.com. Get the full analysis behind how media bias impacts breaking news.

Overall, we’ve indexed 100 stories from urologytime.com over the past 3 months.

We’ve assigned a media bias rating of unknown to urologytime.com. You can read more about our methodology here.

urologytime.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about urologytime.com

Where is urologytime.com located?urologytime.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

100% Right coverage: 1 sources

Research reveals that lower PSA levels in metastatic hormone-sensitive prostate cancer significantly delay disease progression and improve patient outcomes.Research See the Story

Representation of Black men with mHSPC in clinical trials

Explore the critical underrepresentation of black men in metastatic hormone sensitive prostate cancer trials and its implications for treatment outcomes.See the Story

BPH: Strategies for Guiding Patients From Medication to Intervention

Panelist discusses how hospitals benefit from adopting aqua ablation therapy by improving surgical efficiency, reducing turnover times, enabling outpatient procedures, and providing a highly effective treatment option that can enhance patient outcomes while preserving sexual function.See the Story

Strengths and Weaknesses of Imaging Modalities in ccRCC

Explore the strengths and weaknesses of imaging modalities like CT, MRI, and ultrasound in diagnosing ccRCC and enhancing patient care.See the Story

Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

Research highlights the significant benefits of achieving ultra-low PSA levels in metastatic hormone-sensitive prostate cancer, delaying disease progression effectively.Research See the Story

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.Maryland · Maryland Read Article

News from urologytime.com

News from urologytime.com

Information about urologytime.com

Media Bias Ratings

Factuality

Ownership

Top urologytime.com News

Surgeons in California Perform First-Ever Human Bladder Transplant

Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists

Biden’s Cancer Treatment Plan Might Not Involve Chemotherapy

Patient selection for cytoreductive nephrectomy in 2025

Treatment or Lack of Treatment of Small Renal Masses

Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

Representation of Black men with mHSPC in clinical trials

BPH: Strategies for Guiding Patients From Medication to Intervention

Strengths and Weaknesses of Imaging Modalities in ccRCC

Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Similar News Topics

Topics Most Covered by urologytime.com

Sources Covering Similar Topics

Breaking News Topics Related to urologytime.com

Information about urologytime.com

Media Bias Ratings

Factuality

Ownership

Patient selection for cytoreductive nephrectomy in 2025

Treatment or Lack of Treatment of Small Renal Masses

Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

Representation of Black men with mHSPC in clinical trials

BPH: Strategies for Guiding Patients From Medication to Intervention

Strengths and Weaknesses of Imaging Modalities in ccRCC

Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD